![Epic EHR data: Cancer screenings nosedive in 2021 despite easing of COVID restrictions](https://cdn.cancerletter.com/media/2021/09/17171029/47-34-screening-4x3-1.jpg)
![Epic EHR data: Cancer screenings nosedive in 2021 despite easing of COVID restrictions](https://cdn.cancerletter.com/media/2021/09/17171029/47-34-screening-4x3-1.jpg)
Cover Story
Real-world Evidence
Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- Tweaking the existing systems is not the answer to drug shortages